Operational highlights and financial results for the year ended june 30, 2021

New york, aug. 30, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the fourth quarter and full-year ended june 30, 2021 (fy2021).
MESO Ratings Summary
MESO Quant Ranking